In recent years, the emergence of immunotherapy has provided a new perspective for the treatment and management of triple-negative breast cancer (TNBC). However, the relationship between tumor mutatio

NIAID Data Ecosystem40

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study

非小细胞肺癌精准治疗

分子检测临床应用

BackgroundThe goals of this multinational retrospective study were to describe treatment patterns and survival outcomes by receipt of molecular testing and molecular status of patients with advanced n

Figshare2018-08-27 更新20

Supplementary Table 3 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations

非小细胞肺癌精准治疗

PDX模型药物评估

Supplementary Table 3(A)Establishment status by histological subtype(B)Establishment status by gene aberration.

NIAID Data Ecosystem40

Table_2_Organoid drug screening report for a non-small cell lung cancer patient with EGFR gene mutation negativity: A case report and review of the literature.doc

类器官药物筛选

非小细胞肺癌精准治疗

Patients with non-small cell lung cancer (NSCLC) who carry epidermal growth factor receptor (EGFR) mutations can benefit significantly from EGFR tyrosine kinase inhibitors (EGFR TKIs). However, it is

NIAID Data Ecosystem30

Summary of prognostic impact of Exon20 insertions compared to other genotypes.

资源简介：

相关数据集